Advertisement

Topics

Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

2014-08-27 03:15:48 | BioPortfolio

Summary

The purpose of this study is to explore the safety and activity of docetaxel + ASA404 as second-line chemotherapy in patients with advanced urothelial carcinoma.

Description

OUTLINE: This is a multi-center study.

21 Day Cycle Treatment Regimen:

- Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1

- ASA404 (given after Docetaxel) IV 1800 mg/m2 over approximately 20 minutes on Day 1

Treatment will continue until disease progression or intolerable treatment related adverse effects.

Karnofsky performance status of ≥ 70% within 7 days prior to registration for protocol therapy.

Life Expectancy: Not specified

Hematopoietic:

- Hemoglobin (Hgb) > 9 g/dL

- Platelets > 100 K/mm3

- Absolute neutrophil count (ANC) > 1.5 K/mm3

- INR or Prothrombin Time (PT) < 1.5 x ULN

Hepatic:

- Bilirubin < 1.5 x ULN

- Aspartate aminotransferase (AST, ALT) < 2.5 x ULN

Renal:

- Calculated creatinine clearance of > 45 cc/min using the Cockcroft-Gault formula

Cardiovascular:

- No congestive heart failure (NY Heart Association class III or IV)

- No myocardial infarction within 12 months of study registration for protocol therapy or with implanted cardiac pacemaker

- No unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Urothelial Carcinoma

Intervention

Docetaxel, ASA404

Location

Indiana University Melvin & Bren Simon Cancer Center
Indianapolis
Indiana
United States
46202

Status

Not yet recruiting

Source

Hoosier Oncology Group

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:15:48-0400

Clinical Trials [1892 Associated Clinical Trials listed on BioPortfolio]

The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence

The investigators evaluated the efficacy of a single early intravesical instillation of doxetaxel in the prevention of bladder recurrence after nephroureterectomy or distal ureterectomy fo...

A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer

This study evaluates the safety and efficacy of the combination of Avelumab, (a fully human anti-programmed death ligand 1 (PD-L1) IgG1 antibody) in combination with a taxane chemotherapy ...

A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma

The purpose of this study is to evaluate the overall response rate (ORR) of INCB054828 as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harbo...

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFRpositive locall...

Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma

Primary Objective: To study if lycopene can improve the biomarker status of urothelial cells in patients with uremia-associated urothelial carcinoma. Secondary Objective: To evaluate the ...

PubMed Articles [3375 Associated PubMed Articles listed on BioPortfolio]

Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma.

Current literature supports the efficacy of anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors for the treatment of urothelial carcinomas. While the prognostic value of PD-1 and PD-L1 levels has be...

Immunohistochemistry of CK5/6, CD44, and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.

Immunohistochemical (IHC) staining for CK5/6, CD44, and CK20 has been significantly associated with the prognosis of urinary bladder urothelial carcinoma and probably reflects its molecular characteri...

Ureteral pseudodiverticulosis and urothelial cell carcinoma: rethinking the association.

To compare frequency of new and recurrent urothelial cell carcinoma (UCC) among patients with and without pseudodiverticulosis on imaging.

Comparison of Renal Function after Radical Surgery for Upper Tract Urothelial Carcinoma versus Renal Cell Carcinoma: Propensity Score Matching.

To compare renal function after radical nephrectomy for renal cell carcinoma (RCC) and for upper tract urothelial carcinoma (UTUC).

MicroRNA expression profiles in upper tract urothelial carcinoma differentiate tumor grade, stage and survival: implications for clinical decision-making.

To evaluate microRNA biomarkers for upper tract urothelial carcinoma (UTUC) to improve risk stratification.

Medical and Biotech [MESH] Definitions

A condition in which abnormal cells have not spread outside the duct, lobule, or nipple to other tissues of the breast. There are 3 types of breast carcinoma in situ: DUCTAL CARCINOMA IN SITU; LOBULAR CARCINOMA IN SITU; and PAGET DISEASE OF THE NIPPLE

A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)

An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.

More From BioPortfolio on "Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...


Searches Linking to this Trial